摘要
替格瑞洛属于新型P2Y12受体强效拮抗药,对二磷酸腺苷诱导的血小板聚集反应能产生呈浓度依赖和可逆的抑制作用,在临床上作为常用的抗血小板药被广泛用于治疗急性冠脉综合征。在替格瑞洛管理急性冠脉综合征患者过程中发生缓慢性心律失常不良反应的可能性不大,但一旦发生有可能是致命性的。现重点阐述替格瑞洛在治疗急性冠脉综合征时缓慢性心律失常的发生率、机制、可能的危险因素、特点、干预及转归等方面的国内外研究进展。
Ticagrelor is a new potent antagonist of P2Y12 receptor,which has a concentration-related and reversible inhibitory effect on the platelet aggregation response induced by adenosine diphosphate.As a commonly used antiplatelet drug,it is widely used in the treatment of acute coronary syndrome.The incidence of bradyarrhythmia in patients with acute coronary syndrome treated with ticagrelor is low,but it may be fatal if it occurs.This article focuses on the research progress of incidence,mechanism,possible risk factors,characteristics,intervention and outcome of bradyarrhythmia by ticagrelor in the treatment of acute coronary syndrome at home and abroad.
作者
王晓妍
崔炜
WANG Xiaoyan;CUI Wei(Department of Cardiology,The Second Hospital of Hebei Medical University and Institute of Cardiocerebrovascular Disease of Hebei Province,Shijiazhuang 050000,Hebei,China)
出处
《心血管病学进展》
CAS
2021年第7期642-644,657,共4页
Advances in Cardiovascular Diseases
